Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R21 Clinical Trial Optional)
Funding Opportunity RFA-AT-19-009 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Center for Complementary and Integrative Health (NCCIH) solicits grant research applications to study minor cannabinoids and terpenes in the cannabis plant as it relates to pain and nociception. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than ?9-tetrahydrocannabinol (?9-THC). Cannabinoids and terpenes of particular interest include the following: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 3, 2019 Category: Research Source Type: funding
Exploring the Mechanisms Underlying Analgesic Properties of Minor Cannabinoids and Terpenes (R01 Clinical Trial Optional)
Funding Opportunity RFA-AT-19-008 from the NIH Guide for Grants and Contracts. Through this funding opportunity announcement (FOA), the National Center for Complementary and Integrative Health (NCCIH) solicits grant research applications to study minor cannabinoids and terpenes in the cannabis plant as it relates to pain and nociception. Minor cannabinoids are defined as any and all cannabinoids from the cannabis plant other than ?9-tetrahydrocannabinol (?9-THC). Cannabinoids and terpenes of particular interest include the following: Cannabidiol (CBD), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Myrcene...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 3, 2019 Category: Research Source Type: funding
Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-104 from the NIH Guide for Grants and Contracts. As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcri...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 14, 2018 Category: Research Source Type: funding
Notice for the All of Us Research Program Genetic Counseling Resource Funding Opportunity and Informational Webinar
Notice NOT-PM-19-001 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 30, 2018 Category: Research Source Type: funding
Genetic Engineering Technologies for HIV Cure Research (U19 Clinical Trial Optional)
Funding Opportunity RFA-AI-18-058 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to apply genetic engineering technologies to HIV-1 cure research. Gene- and/or cell-based approaches are sought that can achieve long term remission of HIV-1 in the absence of antiretroviral treatment or complete elimination of HIV-1. Applications are expected to include basic science/preclinical research as well as translational activities such as test-of-concept studies in animal models or human subjects and must be designed as collaborative efforts between academia and the priva...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 29, 2018 Category: Research Source Type: funding
Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-079 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics. (Source: NIH Funding Opportuni...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 26, 2018 Category: Research Source Type: funding
Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-078 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics. (Source: NIH Funding Opportuni...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 26, 2018 Category: Research Source Type: funding
Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03 - Clinical Trial Not Allowed)
Funding Opportunity PAR-19-069 from the NIH Guide for Grants and Contracts. REISSUE of PAR-18-733 The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diag...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 16, 2018 Category: Research Source Type: funding
Collaborative Study on the Genetics of Alcoholism (COGA) (Clinical Trial Not Allowed U10)
Funding Opportunity RFA-AA-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) issued by the National Institute on Alcoholism and Alcohol Abuse (NIAAA), solicits cooperative agreement (U10) applications focusing on studies that (i) identify genetic variants that affect the susceptibility to develop alcohol dependence in adult and adolescent populations, (ii) determine molecular and functional mechanisms of these variants, (iii) identify and characterize gene x gene and gene x environment interactions leading to alcoholism, (iv) develop and refine phenotypes that will facilitat...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 5, 2018 Category: Research Source Type: funding
NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
Funding Opportunity PAR-19-048 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. Successful applicants will provide biospecimens for whole genome sequencing or other omics assays. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public database such as dbGaP. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 1, 2018 Category: Research Source Type: funding
Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed)
Funding Opportunity PA-19-043 from the NIH Guide for Grants and Contracts. Genome-wide association studies and other disease studies have identified many variants that are statistically associated with disease risk, disease protection, or other traits. However, such studies do not generally show which specific variants in genomic elements cause these effects, or how they result in differences in function. Similarly, genomic sequencing studies in clinical settings have identified many variants in healthy and diseased individuals. However, the pathogenicity of such variants is often unknown, leading to their classificatio...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 31, 2018 Category: Research Source Type: funding
Specialized Alcohol Research Centers Clinical Trial Optional (P50 Clinical Trial Optional)
Funding Opportunity RFA-AA-19-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for specialized Alcohol Research Centers using the P50 mechanism. The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institutes mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorders and their biomedical, psychosocial, and economic cons...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 11, 2018 Category: Research Source Type: funding
Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional)
Funding Opportunity RFA-DK-18-017 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains....
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 12, 2018 Category: Research Source Type: funding
Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional)
The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this Funding Opportunity Announcement (FOA) is to expand the numbe...
Source: NIDDK Funding Opportunities - September 12, 2018 Category: Endocrinology Source Type: funding
Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01 Clinical Trial Optional).
Funding Opportunity RFA-CA-19-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative) that is intended to accelerate cancer research. The purpose of this FOA is to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer. Specifically, this FOA targets the f...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 10, 2018 Category: Research Source Type: funding
